Penumbra Seen as 'Strategic and Financial Fit' for Boston Scientific, RBC Says

MT Newswires Live

Feb 27

Penumbra (PEN) is a strong "strategic and financial" fit for Boston Scientific (BSX) and the pending merger is expected to support Boston Scientific's growth profile, RBC Capital Markets said.

The company's Q4 beat was driven by notable outperformance in embolization and access segments. Total revenue came in at about $385 million, up roughly 21% year on year. Adjusted EPS came in at $1.18, beating the consensus of $1.11, the brokerage said in a Wednesday note.

The investment firm expects 2026 adjusted EPS of $5.19 and revenue of $1.61 billion.

RBC noted that Penumbra has a large addressable patient population for intervention and immersive health and it will continue to be a leader in the neurovascular segment.

The brokerage has a sector perform rating on the stock, with a $374 price target.

Price: 339.99, Change: +1.32, Percent Change: +0.39

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614024573"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614024573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614024573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614024573","market":"hk","top_or_hot":-1,"title":"Penumbra Seen as 'Strategic and Financial Fit' for Boston Scientific, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Penumbra (PEN) is a strong \"strategic and financial\" fit for Boston Scientific (BSX) and the pending merger is expected to support Boston Scientific's growth profile, RBC Capital Markets said.</p><p>The company's Q4 beat was driven by notable outperformance in embolization and access segments. Total revenue came in at about $385 million, up roughly 21% year on year. Adjusted EPS came in at $1.18, beating the consensus of $1.11, the brokerage said in a Wednesday note.</p><p>The investment firm expects 2026 adjusted EPS of $5.19 and revenue of $1.61 billion.</p><p>RBC noted that Penumbra has a large addressable patient population for intervention and immersive health and it will continue to be a leader in the neurovascular segment.</p><p>The brokerage has a sector perform rating on the stock, with a $374 price target.</p><p>Price: 339.99, Change: +1.32, Percent Change: +0.39</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Seen as 'Strategic and Financial Fit' for Boston Scientific, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Seen as 'Strategic and Financial Fit' for Boston Scientific, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 01:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Penumbra (PEN) is a strong \"strategic and financial\" fit for Boston Scientific (BSX) and the pending merger is expected to support Boston Scientific's growth profile, RBC Capital Markets said.</p><p>The company's Q4 beat was driven by notable outperformance in embolization and access segments. Total revenue came in at about $385 million, up roughly 21% year on year. Adjusted EPS came in at $1.18, beating the consensus of $1.11, the brokerage said in a Wednesday note.</p><p>The investment firm expects 2026 adjusted EPS of $5.19 and revenue of $1.61 billion.</p><p>RBC noted that Penumbra has a large addressable patient population for intervention and immersive health and it will continue to be a leader in the neurovascular segment.</p><p>The brokerage has a sector perform rating on the stock, with a $374 price target.</p><p>Price: 339.99, Change: +1.32, Percent Change: +0.39</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989764748.USD","symbol_name":"东方汇理环球颠覆性机遇A2 Acc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614024573","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614024573","pubTimestamp":1772125890,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Penumbra  is a strong \"strategic and financial\" fit for Boston Scientific  and the pending merger is expected to support Boston Scientific's growth profile, RBC Capital Markets said.The company's Q4 beat was driven by notable outperformance in embolization and access segments. Total revenue came in at about $385 million, up roughly 21% year on year. Adjusted EPS came in at $1.18, beating the consensus of $1.11, the brokerage said in a Wednesday note.The investment firm expects 2026 adjusted EPS of $5.19 and revenue of $1.61 billion.RBC noted that Penumbra has a large addressable patient population for intervention and immersive health and it will continue to be a leader in the neurovascular segment.The brokerage has a sector perform rating on the stock, with a $374 price target.Price: 339.99, Change: +1.32, Percent Change: +0.39","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","BK4585":"ETF&股票定投概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK7095":"多种金属与采矿","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK7083":"煤与消费用燃料","BSX":"波士顿科学","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4082":"医疗保健设备","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4504":"桥水持仓","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","PEN":"Penumbra Inc","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","BK4588":"碎股","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","PEN.AU":"PENINSULA ENERGY LTD","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BSX.AU":"BLACKSTONE MINERALS LTD","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4581":"高盛持仓","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"translate_title":"加拿大皇家银行表示，半影被视为波士顿科学公司的“战略和财务契合度”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN.AU":1,"BSX":1.5,"PEN":1.5,"BSX.AU":1},"content_text":"Penumbra (PEN) is a strong \"strategic and financial\" fit for Boston Scientific (BSX) and the pending merger is expected to support Boston Scientific's growth profile, RBC Capital Markets said.The company's Q4 beat was driven by notable outperformance in embolization and access segments. Total revenue came in at about $385 million, up roughly 21% year on year. Adjusted EPS came in at $1.18, beating the consensus of $1.11, the brokerage said in a Wednesday note.The investment firm expects 2026 adjusted EPS of $5.19 and revenue of $1.61 billion.RBC noted that Penumbra has a large addressable patient population for intervention and immersive health and it will continue to be a leader in the neurovascular segment.The brokerage has a sector perform rating on the stock, with a $374 price target.Price: 339.99, Change: +1.32, Percent Change: +0.39","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}